Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.

ABSTRACT: The combination of two immune checkpoint inhibitors (CPI) or a CPI with a tyrosine kinase inhibitor (TKI) has expanded the therapeutic options for advanced/metastatic renal cell carcinoma (aRCC) beyond TKI monotherapy. In the absence of head-to-head randomized trials comparing these strategies, we estimate their real-world effectiveness by emulating a hypothetical randomized trial. A total of 936 patients with aRCC from the prospective, observational, multicenter clinical registry CARAT (NCT03374267) starting first-line treatment after January 15, 2019, were included. Inverse probability of treatment weighting (IPTW) was used to compare first-line CPI + TKI (n = 447), CPI + CPI (n = 257), and TKI monotherapy (n = 166). Real-world progression-free survival (rwPFS), overall survival (OS), an

SUBMITTER: Goebell PJ 

PROVIDER: S-EPMC12811213 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature